Trial Profile
A Phase 3 Randomized, Double-Blind Study Assessing The Efficacy And Safety Of PF-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms REFLECTIONS B537-02
- Sponsors Pfizer
- 14 Jan 2020 Results of long-term efficacy and safety data from weeks 54 to 78 published in the BioDrugs.
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 16 Jun 2018 Results assessing efficacy and safety of Gp1111 from week 30 to week 54, presented at the 19th Annual Congress of the European League Against Rheumatism